Domoprednate
Domoprednate (brand name Stermonid; developmental code name Ro 12-7024) is a synthetic glucocorticoid corticosteroid which was developed in the late 1970s and 1980s.[1][2][3][4][5]
Clinical data | |
---|---|
Trade names | Stermonid |
Other names | Ro 12-7024; 11β-Hydroxy-D-homopregna-1,4-diene-3,20-dione 17α-butyrate |
Routes of administration | Topical |
Drug class | Corticosteroid; Glucocorticoid |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
ECHA InfoCard | 100.060.441 |
Chemical and physical data | |
Formula | C26H36O5 |
Molar mass | 428.569 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
References
- J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 465–. ISBN 978-1-4757-2085-3.
- Schmidt H, Hjorth N, Holm P (1984). "A randomized trial on the D-homosteroid domoprednate (Ro 12-7024) in the treatment of dermatoses". Dermatologica. 168 (3): 127–30. doi:10.1159/000249683. PMID 6370748.
- Serup J, Holm P (1985). "Domoprednate (Stermonid), a topical D-homocorticosteroid, skin atrophy and telangiectasia. A double-blind, randomized comparison with hydrocortisone butyrate, betamethasone valerate, clobetasole propionate and placebo". Dermatologica. 170 (4): 189–94. doi:10.1159/000249529. PMID 3888708.
- Christiansen JV, Foged E, Holm P, Jørgensen AS, Reymann F (1985). "The treatment of psoriasis with 0.1% domoprednate (a D-homocorticosteroid) and 0.1% betamethasone valerate ointment. A double-blind, randomized trial". Dermatologica. 170 (4): 195–8. doi:10.1159/000249530. PMID 3888709.
- Schmidt H, Hjorth N, Holm P (1987). "Domoprednate, a new nonhalogenated topical steroid: comparison to hydrocortisone butyrate". Dermatologica. 175 (3): 145–7. doi:10.1159/000248813. PMID 3653463.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.